Generation Bio Appoints Matthew Norkunas, M.D., MBA as Chief Financial Officer
“We are delighted to add Matt’s broad strategic perspective and deep operational experience to our team as we prepare the platform for our journey to the clinic,” said
“I have long believed that precision medicine has the power to transform our world, and I’m excited to join a team that is developing a way to do that at scale,”
Generation Bio is an innovative genetic medicines company focused on creating a new class of non-viral gene therapy to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral platform incorporates a proprietary, high-capacity DNA construct called closed-ended DNA, or ceDNA; a cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The platform is designed to enable multi-year durability from a single dose of ceDNA, and to allow titration and redosing if needed. The ctLNP is designed to deliver large genetic payloads, including multiple genes, to specific tissues to address a wide range of indications. The company’s efficient, scalable manufacturing process supports Generation Bio’s mission to extend the reach of gene therapy to more people, living with more diseases, in more places around the world.
For more information, please visit www.generationbio.com.
Source: Generation Bio Co.